IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Renal biopsy specimens were obtained from five patients with IgA nephropathy (IgAN), five patients with membranous nephropathy (MN) and five kidney transplant donors (as controls).
|
31707756 |
2020 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background</b>: Circulating B cells are crucial for the pathogenesis of IgA nephropathy (IgAN).
|
31670996 |
2020 |
IGA Glomerulonephritis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Galactose-deficient IgA1 (Gd-IgA1) plays a crucial role in the development of IgA nephropathy (IgAN).
|
31748116 |
2020 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common and heterogeneous glomerular nephropathy.
|
30902505 |
2020 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunoglobulin A (IgA) vasculitis with nephritis (IgAVN) and IgA nephropathy (IgAN) are widely considered as related diseases.
|
30838755 |
2020 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is one the most common primary glomerulonephritis in children and adolescents worldwide, with 20% of children developing end-stage kidney disease (ESKD) within 20 years of diagnosis.
|
30778826 |
2020 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most prevalent primary chronic glomerular disease for which no safe disease-specific therapies currently exist.
|
31027890 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide.
|
31275309 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide and is an important cause of end-stage renal disease (ESRD).
|
31272400 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to evaluate the value of urinary angiostatin levels for assessing disease severity and progression of IgA nephropathy (IgAN).
|
30943905 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies.
|
30635299 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide.
|
31464185 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and a common cause of end-stage renal disease.
|
30941137 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although IgA nephropathy (IgAN) is the most common glomerulonephritis in the world, there is no validated tool to predict disease progression.
|
30980653 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most prevalent cause of primary glomerular disease worldwide, and the cytokine A PRoliferation-Inducing Ligand (APRIL) is emerging as a key player in IgAN pathogenesis and disease progression.
|
30761651 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide and up to 40% will develop end-stage renal disease (ESRD) within 20 years.
|
31317004 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Strong experimental and clinical evidence, the Clinical Practice Guidelines for IgA Nephropathy in Japan, the Oxford Classification, and the Kidney Disease Improving Global Outcomes guidelines have all contributed to the appropriate treatment of IgAN.
|
30968243 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Focal segmental glomerular sclerotic lesions in IgA nephropathy (IgAN), considered for years a chronic histologic feature related to proteinuria in remnant nephrons without any active role in the pathogenesis and progression of glomerular damage of IgAN, have been recently reconsidered.
|
31773265 |
2019 |
IGA Glomerulonephritis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Studies have shown that the occurrence and development of IgA nephropathy (IgAN) are genetically susceptible, but the relationship between vitamin D receptor (<i>VDR</i>) gene polymorphisms and renal function in IgAN patients is unclear.
|
31218132 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The efficacy and safety of glucocorticoids for the treatment of patients with IgA nephropathy (IgAN) remains controversial.
|
30843135 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is primarily resulted of qualitative abnormality of IgA.
|
31815288 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The serum immunoglobulin A (IgA)/C3 ratio is considered to be an effective predictor of IgA nephropathy (IgAN).
|
31039758 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the commonest global cause of glomerulonephritis.
|
31296183 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) as the commonly used renin-angiotensin aldosterone system inhibitor are widely used in patients with IgA nephropathy (IgAN), but the effect is controversy.
|
31700813 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prognosis of patients with allograft IgA nephropathy (IgAN) requires further investigation.
|
29718591 |
2019 |